Perhaps the most relevant statistics data that we could gather is presented here:
Data type/Website parameter | Status or value | Our findings |
---|---|---|
Site title (meta) | About GAZYVA® (obinutuzumab) Treatment | Sticking to between 50-60 characters for meta title length is a good idea. The length of this website's meta title is 38. |
Website meta description | Learn about GAZYVA® in first-line FL, relapsed/refractory follicular lymphoma, and previously untreated chronic lymphocytic leukemia treatment. Indication: GAZYVA® (obinutuzumab) is a prescription medicine used with the chemotherapy drug, chlorambucil, to treat chronic lymphocytic leukemia (CLL) in adults who have not had previous CLL treatment. GAZYVA® (obinutuzumab) is a prescription medicine used with the chemotherapy drug, bendamustine, followed by GAZYVA alone for follicular lymphoma (FL) in adults who did not respond to a rituximab-containing regimen, or whose FL returned after such treatment. GAZYVA® (obinutuzumab) is a prescription medicine used in combination with chemotherapy, followed by GAZYVA alone in those who responded, to treat stage II bulky, III or IV follicular lymphoma (FL) in adults who have not had previous FL treatment.IMPORTANT SAFETY INFORMATION: What is the most important safety information I should know about GAZYVA? Tell your doctor right away about any side effect you experience. GAZYVA can cause side effects that can become serious or life threatening, including: Hepatitis B Virus (HBV): Hepatitis B can cause liver failure and death. If you have a history of hepatitis B infection, GAZYVA could cause it to return. You should not receive GAZYVA if you have active hepatitis B liver disease. Your doctor or healthcare team will need to screen you for hepatitis B before, and monitor you during and after, your treatment with GAZYVA. Sometimes this will require treatment for hepatitis B. Symptoms of hepatitis include: worsening of fatigue and yellow discoloration of skin or eyes. Progressive Multifocal Leukoencephalopathy (PML): PML is a rare and serious brain infection caused by a virus. PML can be fatal. Your weakened immune system could put you at risk. Your doctor will watch for symptoms. Symptoms of PML include: confusion, difficulty talking or walking, dizziness or loss of balance, and vision problems. Who should not receive GAZYVA? Do NOT receive GAZYVA if you have had an allergic reaction (e.g., anaphylaxis or serum sickness) to GAZYVA. Tell your healthcare provider if you have had an allergic reaction to obinutuzumab or any other ingredients in GAZYVA in the past. What are the additional possible serious side effects of GAZYVA? Tell your doctor right away about any side effect you experience. GAZYVA can cause side effects that may become severe or life threatening, including: Reactions: These side effects may occur during or within 24 hours of any GAZYVA infusion. Some infusion reactions can be serious, including, but not limited to, severe allergic reactions (anaphylaxis), acute life-threatening breathing problems, or other life-threatening infusion reactions. If you have a reaction, the infusion is either slowed or stopped until your symptoms are resolved. Most patients are able to complete infusions and receive medication again. However, if the infusion reaction is life threatening, the infusion of GAZYVA will be permanently stopped. Your healthcare team will take steps to help lessen any side effects you may have to the infusion process. You may be given medicines to take before each GAZYVA treatment. Symptoms of infusion reactions may include: fast heartbeat, tiredness, dizziness, headache, redness of the face, nausea, chills, fever, vomiting, diarrhea, rash, high blood pressure, low blood pressure, difficulty breathing, and chest discomfort. Hypersensitivity Reactions Including Serum Sickness: Some people receiving GAZYVA may have severe or life-threatening allergic reactions. This reaction may be severe, may happen during or after an infusion, and may affect many areas of the body. If an allergic reaction occurs, your doctor will stop the infusion and permanently discontinue GAZYVA. Tumor Lysis Syndrome (TLS): Tumor lysis syndrome, including fatal cases, has been reported in patients receiving GAZYVA. GAZYVA works to break down cancer cells quickly. As cancer cells break apart, their contents are released into the blood. These contents may cause damage to organs and the heart, and may lead to kidney failure requiring the need for dialysis treatment. Your doctor may prescribe medication to help prevent TLS. Your doctor will also conduct regular blood tests to check for TLS. Symptoms of TLS may include nausea, vomiting, diarrhea, and tiredness. Infections: While you’re taking GAZYVA, you may develop infections. Some of these infections may be fatal and severe, so be sure to talk to your doctor if you think you have an infection. Patients administered GAZYVA in combination with chemotherapy, followed by GAZYVA alone are at a high risk of infections during and after treatment. Patients with a history of recurring or chronic infections may be at an increased risk of infection. Patients with an active infection should not be treated with GAZYVA. Patients taking GAZYVA plus bendamustine may be at higher risk for fatal or severe infections compared to patients taking GAZYVA plus CHOP or CVP. Low White Blood Cell Count: When you have an abnormally low count of infection-fighting white blood cells, it is called neutropenia. While you are taking GAZYVA, your doctor will do blood work to check your white blood cell count. Severe and life-threatening neutropenia can develop during or after treatment with GAZYVA. Some cases of neutropenia can last for more than one month. If your white blood cell count is low, your doctor may prescribe medication to help prevent infections. Low Platelet Count: Platelets help stop bleeding or blood loss. GAZYVA may reduce the number of platelets you have in your blood; having low platelet count is called thrombocytopenia. This may affect the clotting process. While you are taking GAZYVA, your doctor will do blood work to check your platelet count. Severe and life-threatening thrombocytopenia can develop during treatment with GAZYVA. Fatal bleeding events have occurred in patients treated with GAZYVA. If your platelet count gets too low, your treatment may be delayed or reduced. The most common side effects of GAZYVA in CLL were infusion reactions, low white blood cell counts, low platelet counts, low red blood cell counts, fever, cough, nausea, and diarrhea. The safety of GAZYVA was evaluated based on 392 patients with relapsed or refractory NHL, including FL (81%), small lymphocytic lymphoma (SLL) and marginal zone lymphoma (MZL) (a disease for which GAZYVA is not indicated), who did not respond to or progressed within 6 months of treatment with rituximab product or a rituximab product-containing regimen. In patients with follicular lymphoma, the profile of side effects that were seen were consistent with the overall population who had NHL. The most common side effects of GAZYVA were infusion reactions, low white blood cell counts, nausea, fatigue, cough, diarrhea, constipation, fever, low platelet counts, vomiting, upper respiratory tract infection, decreased appetite, joint or muscle pain, sinusitis, low red blood cell counts, general weakness, and urinary tract infection. A randomized, open-label multicenter trial (GALLIUM) evaluated the safety of GAZYVA as compared to rituximab product in 1,385 patients with previously untreated follicular lymphoma (86%) or marginal zone lymphoma (14%). The most common side effects of GAZYVA were infusion reactions, low white blood cell count, upper respiratory tract infection, cough, constipation and diarrhea. What other information should I tell my doctor before receiving GAZYVA? You should talk to your doctor about: Immunizations: Before receiving GAZYVA therapy, tell your healthcare provider if you have recently received or are scheduled to receive a vaccine. People who are treated with GAZYVA should not receive live vaccines. Pregnancy: Tell your doctor if you are pregnant, think that you might be pregnant, plan to become pregnant, or are breastfeeding. GAZYVA may harm your unborn baby. Speak to your doctor about using GAZYVA while you are pregnant. Talk to your doctor or your child’s doctor about the safety and timing of live virus vaccinations to your infant if you received GAZYVA during pregnancy. It is not known if GAZYVA may pass into your breast milk. Speak to your doctor about using GAZYVA if you are breastfeeding. Tell your doctor about any side effects. These are not all of the possible side effects of GAZYVA. For more information, ask your doctor or pharmacist. GAZYVA is available by prescription only. You may report side effects to the FDA at (800) FDA-1088, or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555. Please see the accompanying full Prescribing Information, including BOXED WARNINGS, for additional Important Safety Information. | The length of the meta description is 8749 characters. Google recommends up to around 280-320 characters at the most. |
Metadata keywords | gazyva, obinutuzumab, genentech, roche, CLL, chronic lymphocytic leukemia, chronic lymphocytic leukemia therapy, CLL treatment, follicular lymphoma treatment, refractory FL, relapsed FL, follicular lymphoma | Oh. It's unexpected, to put it mildly, to see meta keywords still being used. After all, they are no longer a ranking factor and associate with spam more than anything else. |
Website load speed | Approximately 2.1923 seconds | It takes too long to load the website – we would suggest the webmaster to look into it. |
Global rank by Quantcast | 756,161, after last update | Based on the gathered data, Quantcast does not consider this website to be popular. Take it for what it's worth. |
Homepage links | Approximately 40 | A good amount of links and nothing to worry about. |
Size of page HTML | 51.5KB | If it were up to us, we'd urge the webmaster to improve. The result isn't very good, you see. Just saying. |
Server data | Server seems to be online. IP adress for this domain is 52.9.213.7. | Due to lack of data, we can't provide a meaningful insight. |
The basic overview not enough? Let's dive deeper.
QUANTCAST is very similar to Alexa, though perhaps enjoys an overall better user opinion even if, by comparison, the data processing company's rank index is smaller. The main interest of QUANTCAST is real-time audience analysis, so again the rank is based on traffic. QUANTCAST gathers this data mainly for advertising purposes of other companies. We know that, so far, QUANTCAST has ranked 172,504,131 websites, give or take a few. With all of this said, Quantcast rank is not really any more useful than that of Alexa and most similar ranking systems. Few of them, if any, take context into account and rate websites purely on traffic numbers (guesstimated, in so many cases). It's by far not the most accurate representation of a website's worth.
What is a server? It's basically a physical storage device (one that, sometimes, makes up several virtual servers for the cheaper shared hosting) that holds all the files and databases associated with a specific website or websites. Obviously, it's a touch more complicated than that (servers also have processors), but the essence is quite simple - your browser contacts the server, which then sends all the neccessary information and files to your computer. Each physical server has a unique IP address assigned to it, too, for easy recognition.
If you need more raw data, here's what we managed to gather:
Header information |
---|
HTTP/1.1 200 OK Accept-Ranges: bytes Content-Type: text/html; charset=UTF-8 Date: Fri, 24 Nov 2017 19:30:42 GMT ETag: "ccbb-55e99a88e7abb" Last-Modified: Wed, 22 Nov 2017 22:15:34 GMT Server: Apache ServerID: web01 Content-Length: 52411 Connection: Close |
WHOIS entry |
---|
Whois Server Version 2.0 Domain names in the .com and .net domains can now be registered with many different competing registrars. Go to http://www.internic.net for detailed information. Domain Name: GAZYVA.COM Registrar: SAFENAMES LTD Sponsoring Registrar IANA ID: 447 Whois Server: whois.safenames.net Referral URL: http://www.safenames.net Name Server: HLRNS1.ROCHE.COM Name Server: NS1.ROCHE.COM Name Server: NS2.ROCHE.COM Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Updated Date: 17-oct-2016 Creation Date: 10-nov-2011 Expiration Date: 10-nov-2017 >>> Last update of whois database: Sat, 29 Apr 2017 14:00:21 GMT <<< For more information on Whois status codes, please visit https://icann.org/epp NOTICE: The expiration date displayed in this record is the date the registrar's sponsorship of the domain name registration in the registry is currently set to expire. This date does not necessarily reflect the expiration date of the domain name registrant's agreement with the sponsoring registrar. Users may consult the sponsoring registrar's Whois database to view the registrar's reported date of expiration for this registration. TERMS OF USE: You are not authorized to access or query our Whois database through the use of electronic processes that are high-volume and automated except as reasonably necessary to register domain names or modify existing registrations; the Data in VeriSign Global Registry Services' ("VeriSign") Whois database is provided by VeriSign for information purposes only, and to assist persons in obtaining information about or related to a domain name registration record. VeriSign does not guarantee its accuracy. By submitting a Whois query, you agree to abide by the following terms of use: You agree that you may use this Data only for lawful purposes and that under no circumstances will you use this Data to: (1) allow, enable, or otherwise support the transmission of mass unsolicited, commercial advertising or solicitations via e-mail, telephone, or facsimile; or (2) enable high volume, automated, electronic processes that apply to VeriSign (or its computer systems). The compilation, repackaging, dissemination or other use of this Data is expressly prohibited without the prior written consent of VeriSign. You agree not to use electronic processes that are automated and high-volume to access or query the Whois database except as reasonably necessary to register domain names or modify existing registrations. VeriSign reserves the right to restrict your access to the Whois database in its sole discretion to ensure operational stability. VeriSign may restrict or terminate your access to the Whois database for failure to abide by these terms of use. VeriSign reserves the right to modify these terms at any time. The Registry database contains ONLY .COM, .NET, .EDU domains and Registrars. Domain Name: GAZYVA.COM Registry Domain ID: 1686469138_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.safenames.net Registrar URL: http://www.safenames.net Updated Date: 2016-10-17T13:44:57Z Creation Date: 2011-11-10T09:24:17Z Registrar Registration Expiration Date: 2017-11-10T09:24:17Z Registrar: Safenames Ltd Registrar IANA ID: 447 Registrar Abuse Contact Email: Registrar Abuse Contact Phone: +44.1908200022 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Registry Registrant ID: Not Available From Registry Registrant Name: Domain Administrator Registrant Organisation: Genentech, Inc Registrant Street: 1 DNA Way Registrant Street: Registrant City: South San Francisco Registrant State/Province: CA Registrant Postal Code: 94080 Registrant Country: US Registrant Phone: +1.6502257923 Registrant Fax: Registrant Email: Global. Registry Admin ID: Not Available From Registry Admin Name: global. Admin Organisation: F. Hoffmann-La Roche AG Admin Street: Grenzacherstrasse 124 Admin Street: Admin City: Basel Admin State/Province: Basel Admin Postal Code: 4070 Admin Country: CH Admin Phone: +41.55578787 Admin Fax: Admin Email: global. Registry Tech ID: Not Available From Registry Tech Name: International Domain Tech Tech Organisation: International Domain Tech Tech Street: Safenames House, Sunrise Parkway Tech Street: Tech City: Milton Keynes Tech State/Province: Bucks Tech Postal Code: MK14 6LS Tech Country: UK Tech Phone: +44.1908200022 Tech Fax: +44.1908325192 Tech Email: Name Server: HLRNS1.ROCHE.COM Name Server: NS1.ROCHE.COM Name Server: NS2.ROCHE.COM DNSSEC: unsigned URL of the ICANN WHOIS Data Problem Reporting System: http://wdprs.internic.net/ >>> Last update of WHOIS database: 2016-10-17T13:44:57Z <<< "For more information on Whois status codes, please visit https://icann.org/epp" Safenames - Experts in Global Domain Management and Online Brand Protection Domain Registration in over 760 different extensions Enterprise Domain Management since 1999 Mark Protect™ Online Brand Monitoring and Enforcement Domain Consulting and Strategy Domain Name Acquisition Domain Disputes and Recovery Visit Safenames at www.safenames.net +1 703 574 5313 in the US/Canada +44 1908 200022 in Europe The Data in the Safenames Registrar WHOIS database is provided by Safenames for information purposes only, and to assist persons in obtaining information about or related to a domain name registration record. Safenames does not guarantee its accuracy. Additionally, the data may not reflect updates to billing contact information. By submitting a WHOIS query, you agree to use this Data only for lawful purposes and that under no circumstances will you use this Data to: (1) allow, enable, or otherwise support the transmission of mass unsolicited, commercial advertising or solicitations via e-mail, telephone, or facsimile; or (2) enable high volume, automated, electronic processes that apply to Safenames (or its computer systems). The compilation, repackaging, dissemination or other use of this Data is expressly prohibited without the prior written consent of Safenames. Safenames reserves the right to terminate your access to the Safenames Registrar WHOIS database in its sole discretion, including without limitation, for excessive querying of the WHOIS database or for failure to otherwise abide by this policy. Safenames reserves the right to modify these terms at any time. By submitting this query, you agree to abide by this policy. |
Typos are not uncommon, not even with website addresses. More than that, the more popular the website, the more typos there tend to happen. We have gathered and generated the following list of most frequently encountered mistypes for gazyva.com:
Here is a list of some more reports for you to check. If you found this one on gazyva.com useful, the following list will be of interest to you, too:
This list contains 370 top level domain variantions for gazyva.com domain name: